DeepMed Research

Shanghai Jiaotong Medical University Attached Ruijin Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia

Recruiting

Conditions: Alzheimer Disease
Image

First Posted Date: 2024-08-02

Last Posted Date: 2024-08-02

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 1000

Registration Number: NCT06534658

Locations: 🇨🇳
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳
Chinese People's Liberation Army General Hospital, Beijing, Beijing, China
🇨🇳
First Affiliated Hospital of Zhejiang University School of Medicine, Hanzhong, Hangzhou, China

and more 5 locations

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

Phase 3

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: zanubrutinib, rituximab and lenalidomide
Drug: polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide

First Posted Date: 2024-07-26

Last Posted Date: 2024-08-05

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 100

Registration Number: NCT06522555

Locations: 🇨🇳
Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Phase 2

Recruiting

Conditions: Gastric Cancer Stage IV
Peritoneal Metastases

Interventions: Drug: Cadonilimab, LM-302, S-1, paclitaxel

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-25

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 40

Registration Number: NCT06519591

Locations: 🇨🇳
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Huangpu District, China

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

Early Phase 1

Recruiting

Conditions: Pancreatic Cancer Resectable
Chemotherapy-intolerant

Interventions: Biological: Personalized tumor preventive vaccines
Biological: Fixed neoantigen tumor vaccine
Biological: personalized neoantigen tumor vaccine
Drug: PD-1 inhibitor

First Posted Date: 2024-07-11

Last Posted Date: 2025-04-01

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 20

Registration Number: NCT06496373

Locations: 🇨🇳
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

Phase 3

Recruiting

Conditions: Mantle Cell Lymphoma (MCL)

Interventions: Drug: Orelabrutinib
Drug: Bendamustine
Drug: Venetoclax
Drug: Rituximab

First Posted Date: 2024-07-11

Last Posted Date: 2024-07-11

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 78

Registration Number: NCT06496308

Locations: 🇨🇳
Ruijin Hospital, Shanghai, China

A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

Phase 1

Recruiting

Conditions: Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma

Interventions: Biological: LCAR-HL30 cells

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 32

Registration Number: NCT06494371

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study

Phase 2

Recruiting

Conditions: Esophagogastric Junction Adenocarcinoma

Interventions: Drug: Adebrelimab (anti-PD-L1) + XELOX

First Posted Date: 2024-07-01

Last Posted Date: 2024-07-01

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 26

Registration Number: NCT06482788

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Amygdala TIS for Depression

Not Applicable

Recruiting

Conditions: Major Depressive Disorder

Interventions: Device: Nervio-X

First Posted Date: 2024-06-27

Last Posted Date: 2024-07-09

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 92

Registration Number: NCT06477276

Locations: 🇨🇳
Tianjin Anding Hospital (Mental Health Center of Tianjin Medical University), Tianjin, China
🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
🇨🇳
Shanghai East Hospital, Shanghai, China

A Trial on the Recurrence Free Survival Rate of Type I AIP With High-risk of Recurrence

Phase 4

Recruiting

Conditions: Type 1 AIP

Interventions: Drug: Glucocorticoids+MMF
Drug: Glucocorticoids

First Posted Date: 2024-06-21

Last Posted Date: 2024-06-21

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 86

Registration Number: NCT06468709

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

Signature for Precise Chemosensitivity Prediction in PDAC

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Chemotherapy

First Posted Date: 2024-06-17

Last Posted Date: 2024-06-17

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 365

Registration Number: NCT06461598

Locations: 🇨🇳
Ruijin Hospital, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy